These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 2316314

  • 21. Treatment of macroprolactinomas with a new non-ergot, long-acting dopaminergic drug, CV 205-502.
    van't Verlaat JW, Croughs RJ, Brownell J.
    Clin Endocrinol (Oxf); 1990 Nov; 33(5):619-24. PubMed ID: 1979262
    [Abstract] [Full Text] [Related]

  • 22. Oral and injectable long-lasting bromocriptine preparations in hyperprolactinemia: comparison of their prolactin lowering activity, tolerability and safety.
    Merola B, Colao A, Caruso E, Sarnacchiaro F, Briganti F, Lancranjan I, Lombardi G, Schettini G.
    Gynecol Endocrinol; 1991 Dec; 5(4):267-76. PubMed ID: 1796748
    [Abstract] [Full Text] [Related]

  • 23. Perifusion studies of bromocriptine-treated and untreated macroprolactinomas: effects of dopamine, bromocriptine and TRH.
    Bevan JS, Burke CW.
    Clin Endocrinol (Oxf); 1989 Jun; 30(6):667-80. PubMed ID: 2512041
    [Abstract] [Full Text] [Related]

  • 24. Mixed pituitary tumours--effects of bromocriptine treatment: Parlodel MR and Parlodel LAR.
    Zgliczyński W, Zgliczyński S, Makowska A, Słowinska-Srzednicka J, Janik J, Jeske W, Walecki J.
    Endokrynol Pol; 1992 Jun; 43(3):242-9. PubMed ID: 1345565
    [Abstract] [Full Text] [Related]

  • 25. [Immediate efficacy of bromocriptine (BrC)-LAR in the treatment of macroprolactinomas: apropos of a case].
    García Calzado MC, Ruiz Buendía A.
    Rev Clin Esp; 1992 Jun; 191(2):112-3. PubMed ID: 1502384
    [No Abstract] [Full Text] [Related]

  • 26. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
    Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G.
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
    [Abstract] [Full Text] [Related]

  • 27. Long-acting bromocriptine for the acute treatment of large macroprolactinomas.
    Zarate A, Moran C, Miranda R, Loyo M, Medina M, Fonseca ME.
    J Endocrinol Invest; 1987 Jun; 10(3):233-6. PubMed ID: 3624799
    [Abstract] [Full Text] [Related]

  • 28. [Treatment of macroprolactinomas with delayed bromocriptine. Effectiveness of a single intramuscular injection].
    García-Luna PP, Leal-Cerro A, Pereira JL, Navarro E, Trujillo F, Cortés A, Villamil F, Acosta D, Santos C, Revuelta M.
    Med Clin (Barc); 1990 Feb 03; 94(4):126-9. PubMed ID: 2325463
    [Abstract] [Full Text] [Related]

  • 29. Effects of a new long-acting form of bromocriptine on tumorous hyperprolactinemia.
    Ciccarelli E, Ghigo E, Mazza E, Andreis M, Massara F, Lancranjan I, Camanni F.
    J Endocrinol Invest; 1987 Apr 03; 10(2):179-82. PubMed ID: 3584856
    [Abstract] [Full Text] [Related]

  • 30. Growth of prolactinoma despite lowering of serum prolactin by bromocriptine.
    Kupersmith MJ, Kleinberg D, Warren FA, Budzilovitch G, Cooper P.
    Neurosurgery; 1989 Mar 03; 24(3):417-23. PubMed ID: 2927618
    [Abstract] [Full Text] [Related]

  • 31. Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size.
    van 't Verlaat JW, Croughs RJ.
    Clin Endocrinol (Oxf); 1991 Mar 03; 34(3):175-8. PubMed ID: 2036725
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine.
    Merola B, Sarnacchiaro F, Colao A, Di Somma C, Di Sarno A, Ferone D, Selleri A, Landi ML, Schettini G, Nappi C.
    Gynecol Endocrinol; 1994 Sep 03; 8(3):175-81. PubMed ID: 7847102
    [Abstract] [Full Text] [Related]

  • 36. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
    Glaser B, Nesher Y, Barziliai S.
    J Reprod Med; 1994 Jun 03; 39(6):449-54. PubMed ID: 7932398
    [Abstract] [Full Text] [Related]

  • 37. A long-acting repeatable form of bromocriptine as long-term treatment of prolactin-secreting macroadenomas: a multicenter study.
    Brue T, Lancranjan I, Louvet JP, Dewailly D, Roger P, Jaquet P.
    Fertil Steril; 1992 Jan 03; 57(1):74-80. PubMed ID: 1730334
    [Abstract] [Full Text] [Related]

  • 38. Effectiveness of a single injectable dose of bromocriptine long acting in the treatment of macroprolactinomas.
    Schettini G, Lombardi G, Merola B, Miletto P, Fariello C, Cirillo S, Fusco R, Lancranjan I.
    J Endocrinol Invest; 1988 Jan 03; 11(1):47-51. PubMed ID: 3361075
    [Abstract] [Full Text] [Related]

  • 39. A case of large prolactinoma supposed to be cured by bromocriptine therapy.
    Arita K, Uozumi T, Ohta M.
    Endocrinol Jpn; 1988 Jun 03; 35(3):503-9. PubMed ID: 3197661
    [Abstract] [Full Text] [Related]

  • 40. Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV205-502.
    Barnett PS, Palazidou E, Miell JP, Coskeran PB, Butler J, Dawson JM, Maccabe J, McGregor AM.
    Q J Med; 1991 Nov 03; 81(295):891-906. PubMed ID: 1687293
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.